Evidence map›Paper›PMID 33509238›Full record

ArticleGenome biology2021

ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism.

Valentina Tassinari, Valeriana Cesarini, Sara Tomaselli, Zaira Ianniello, Domenico Alessandro Silvestris, Lavinia Ceci Ginistrelli, Maurizio Martini, Biagio De Angelis, Gabriele De Luca, Lucia Ricci Vitiani and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Targeting RNA adenosine editing and modification enzymes for RNA therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  18. Article
  19. Review
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Valentina TassinariOncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.
Valeriana CesariniOncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.
Sara TomaselliOncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.
Zaira IannielloDepartment of Biology and Biotechnology "Charles Darwin", La Sapienza University of Rome, Rome, Italy.
Domenico Alessandro SilvestrisOncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.
Lavinia Ceci GinistrelliDepartment of Biology and Biotechnology "Charles Darwin", La Sapienza University of Rome, Rome, Italy.
Maurizio MartiniDepartment of Women's, Children's and Public Health Studies, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Largo A. Gemelli 8, 00168, Rome, Italy.
Biagio De AngelisOncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.
Gabriele De LucaDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Lucia Ricci VitianiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161, Rome, Italy.
Alessandro FaticaDepartment of Biology and Biotechnology "Charles Darwin", La Sapienza University of Rome, Rome, Italy.
Franco LocatelliOncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy.
Angela GalloOncohaematology Department, IRCCS Ospedale Pediatrico Bambino Gesu, Viale di San Paolo 15, 00146, Rome, Italy. angela.gallo@opbg.net.
Istituti di Ricovero e Cura a Carattere Scientifico · ITSapienza University of Rome · ITIstituto Superiore di Sanità · ITBambino Gesù Children's Hospital · ITNational Institute of Health · AMNational Research Council · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundN

resultsHere, we show that METTL3, upregulated in glioblastoma, methylates ADAR1 mRNA and increases its protein level leading to a pro-tumorigenic mechanism connecting METTL3, YTHDF1, and ADAR1. We show that ADAR1 plays a cancer-promoting role independently of its deaminase activity by binding CDK2 mRNA, underlining the importance of ADARs as essential RNA-binding proteins for cell homeostasis as well as cancer progression. Additionally, we show that ADAR1 knockdown is sufficient to strongly inhibit glioblastoma growth in vivo.

conclusionsHence, our findings underscore METTL3/ADAR1 axis as a novel crucial pathway in cancer progression that connects m6A and A-to-I editing post-transcriptional events.

Indexed as

AdenosineAdenosine DeaminaseAdultAnimalsCarcinogenesisCell Line, TumorFemaleGene Knockdown TechniquesGlioblastomaHumansMaleMethyltransferasesMutagenesisProtein IsoformsRNA-Binding ProteinsRNA, MessengerADAR protein, humanAdenosineAdenosine DeaminaseMethyltransferasesMETTL3 protein, humanProtein IsoformsRNA-Binding ProteinsRNA, MessengerYTHDF1 protein, human

Identifiers

PMID33509238
PMCPMC7842030
OpenAlexW3125388124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.